Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Preclinical Development: Overview01:28

Preclinical Development: Overview

4.6K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
4.6K
Clinical Trials: Overview01:11

Clinical Trials: Overview

3.2K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
3.2K
Drug Administration and Therapy Phases: Overview01:26

Drug Administration and Therapy Phases: Overview

661
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
661
Drug Discovery: Overview01:26

Drug Discovery: Overview

8.4K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
8.4K
Structure-Activity Relationships and Drug Design01:28

Structure-Activity Relationships and Drug Design

984
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
984
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

162
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
162

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Epigenetic Modulation and Neuroprotective Effects of Neurofabine-C in a Transgenic Model of Alzheimer's Disease.

Genes·2025
Same author

Special Issue: "New Trends in Alzheimer's Disease Research: From Molecular Mechanisms to Therapeutics: 2nd Edition".

International journal of molecular sciences·2025
Same author

Preventive Role of Cocoa-Enriched Extract Against Neuroinflammation in Mice.

Neurology international·2025
Same author

The impact of genetic variability on Alzheimer's therapies: obstacles for pharmacogenetic progress.

Expert opinion on drug metabolism & toxicology·2025
Same author

Therapeutic Options in Alzheimer's Disease: From Classic Acetylcholinesterase Inhibitors to Multi-Target Drugs with Pleiotropic Activity.

Life (Basel, Switzerland)·2025
Same author

Progress in Pharmaceutical Sciences and Future Challenges.

Life (Basel, Switzerland)·2025

Related Experiment Video

Updated: Aug 28, 2025

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

9.7K

New Paradigms in Pharmaceutical Development.

Ramón Cacabelos1

  • 1International Center of Neuroscience and Genomic Medicine, EuroEspes Biomedical Research Center, 15165 Corunna, Spain.

Life (Basel, Switzerland)
|September 23, 2022
PubMed
Summary

Cardiovascular diseases, cancer, and nervous system disorders are the leading causes of illness and death in developed nations. These conditions collectively represent over 80% of the overall disease burden and mortality.

Area of Science:

  • Public Health
  • Epidemiology
  • Internal Medicine

Background:

  • Cardiovascular diseases (CVDs) are the primary health concern in developed countries, accounting for 25-30% of morbidity and mortality.
  • Cancer represents the second leading cause of death, contributing 20-25% to the overall disease burden.
  • Nervous system disorders are also a significant health issue, comprising 10-15% of morbidity and mortality in developed nations.

Discussion:

  • The combined impact of cardiovascular diseases, cancer, and nervous system disorders exceeds 80% of the total morbidity and mortality in developed countries.
  • Understanding the prevalence and impact of these major disease categories is crucial for public health policy and resource allocation.
  • These non-communicable diseases pose a substantial and ongoing challenge to healthcare systems globally.

More Related Videos

Synthesis of Stimuli-responsive Nanogels using Aqueous One-step Crosslinking and Co-nanopolymerization
06:26

Synthesis of Stimuli-responsive Nanogels using Aqueous One-step Crosslinking and Co-nanopolymerization

Published on: January 24, 2025

1.2K
In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing
08:04

In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing

Published on: May 11, 2021

3.0K

Related Experiment Videos

Last Updated: Aug 28, 2025

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

9.7K
Synthesis of Stimuli-responsive Nanogels using Aqueous One-step Crosslinking and Co-nanopolymerization
06:26

Synthesis of Stimuli-responsive Nanogels using Aqueous One-step Crosslinking and Co-nanopolymerization

Published on: January 24, 2025

1.2K
In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing
08:04

In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing

Published on: May 11, 2021

3.0K

Key Insights:

  • Cardiovascular diseases, cancer, and nervous system disorders are the dominant health problems in developed countries.
  • These three disease categories collectively account for a significant majority of illness and death.
  • The data highlights the critical need for targeted prevention and treatment strategies for these prevalent conditions.

Outlook:

  • Future research should focus on integrated approaches to managing these interconnected diseases.
  • Developing effective public health interventions is essential to reduce the burden of these major illnesses.
  • Continued monitoring and analysis of disease trends are vital for adapting healthcare strategies.